Tuberculosis (TB) is one of the world’s most common and life threatening diseases, with over 95% of TB deaths occurring in low- and middle-income countries (WHO, 2015). Some estimates indicate that one third of the world's population is infected with TB.
Some 9.6 million new TB cases occur each year, although many remain undiagnosed and untreated. Vulnerable populations, including children, the poor, and people living with HIV, are at greatest risk for being undiagnosed. Treating TB is possible, but it is difficult and requires long courses of multiple antibiotics. For the 500,000 people who develop multidrug-resistant TB (MDRTB) annually, treatment is more complicated. The second-line drugs used are expensive, hard to access, and often bring painful side effects.
In spite of these challenges, an estimated 49 million lives were saved through TB diagnosis and treatment between 2000 and 2015.
As the procurement agent for the Global Drug Facility (GDF), IDA has supplied ﬁrst- and second-line anti-TB drugs to over 100 countries. Our TB range isn’t limited to medicines. We also supply laboratory equipment for diagnosis and products for patients with HIV/TB coinfection.TB Product Factsheet
In 2015, delamanid and bedaquiline were introduced as the first new TB medicines launched in over 50 years. IDA worked with Otsuka, the manufacturer of delamanid, to ensure continued access to this essential medicine.